Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
2016
Autori:
Steelman, Linda SFitzgerald, Timothy
Lertpiriyapong, Kvin
Cocco, Lucio
Follo, Matilde Y
Martelli, Alberto M
Neri, Luca M
Marmiroli, Sandra
Libra, Massimo
Candido, Saverio
Nicoletti, Ferdinando
Scalisi, Aurora
Fenga, Concettina
Drobot, Lyudmyla
Rakus, Dariusz
Gizak, Agnieszka
Laidler, Piotr
Dulinska-Litewka, Joanna
Basecke, Joerg
Mijatović, Sanja
Maksimović-Ivanić, Danijela
Montalto, Giuseppe
Cervello, Melchiorre
Milella, Michelle
Tafuri, Agustino
Demidenko, Zoya
Abrams, Stephen L
McCubrey, James A
Tip dokumenta:
Članak u časopisu (Objavljena verzija)
,
© 2016 Bentham Science Publishers
Metapodaci
Prikaz svih podataka o dokumentuApstrakt:
The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
Ključne reči:
EGFR; HER2; mIRs; Cancer Stem Cells; Drug Resistance; MetastasisIzvor:
Current Pharmaceutical Design, 2016, 22, 16, 2358-2388Finansiranje / projekti:
- Italian MIUR FIRB grant (RBAP11ZJFA_001)
- East Carolina University School of Medicine Internal Seed Grant Program
DOI: 10.2174/1381612822666160304151011
ISSN: 1381-6128
PubMed: 26947958